Navegando por Palavras-chave "Hodgkin's Lymphoma"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city-a retrospective 14-year study
    (Springer, 2009-07-01) Souza, E. M. [UNIFESP]; Baiocchi, Otavio Carvalho Guimarães [UNIFESP]; Zanichelli, M. A. [UNIFESP]; Alves, A. C. [UNIFESP]; Oliveira, J. S. R. [UNIFESP]; Higienopolis São Paulo; Universidade Federal de São Paulo (UNIFESP)
    The behavior of Hodgkin's lymphoma (HL) is different in developing countries, perhaps due to differences in epidemiology and population access to health care. We performed a retrospective study comparing the efficacy of mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPPABV) versus adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy protocols as first-line therapy for HL in a Brazilian population. A hundred and eighty-six HL patients were retrospectively analyzed regarding their first-line treatment with MOPPABV and ABVD at two public hospitals in SA o pound Paulo, Brazil. Eligible patients were either previously untreated or at first relapse after being treated with only radiotherapy with confirmed HL diagnosis. At a median follow-up of 9 years, complete remission is 89.5 and 85.9 (P = 0.3), overall survival 93.8% and 89.6% (P = 0.68), disease-free survival 85.6% and 81.6% (P = 0.41), and relapse ratios 20.9% and 26.4% (P = 0.17) for ABVD and MOPPABV, respectively. Extended-field radiation therapy postchemotherapy was mostly used in the MOPPABV group. There were three cases of secondary neoplasm (colon adenocarcinoma, myeloid chronic leukemia, and non-Hodgkin's lymphoma), all associated with MOPPABV. ABVD and MOPPABV protocols as first-line treatment for HL resulted in similar therapeutic outcomes and did not influence overall survival, disease-free survival, and relapse ratio. MOPPABV was related to a higher risk of secondary malignancy and, therefore, ABVD should be considered a better option for HL therapy. These findings corroborate recent data in literature.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Ressonância magnética de corpo total com sequência de difusão e FDG-PET/TC: estudo de correlação na avaliação do Linfoma de Hodgkin em crianças, adolescentes e adultos jovens
    (Universidade Federal de São Paulo (UNIFESP), 2019-07-04) Schiavon, Jose Luiz De Oliveira [UNIFESP]; Lederman, Henrique Manoel [UNIFESP]; Ragazzini, Rodrigo [UNIFESP]; http://lattes.cnpq.br/1192557620651923; http://lattes.cnpq.br/6102707812313296; http://lattes.cnpq.br/2987887118534856; Universidade Federal de São Paulo (UNIFESP)
    Objective: Correlate the use of WB-MRI/DWI and FDG-PET/CT on children, adolescents and young adults Hodgkin Lymphoma patients, evaluating if it can be used as an alternative to ionizing radiation exams, on Hodgkin Lymphoma (HL) protocols, during staging and follow-up. Materials and methods: 33 studies from 20 HL patients from our institute, aged from 6 to 20 years old, that had both WB-MRI/DWI and FDG-PET/CT images, during a maximum of 21 day-period between acquiring those methods, were read in consensus by 2 pediatric radiologists, and classified by the presence and major extension of HL on 19 different regions. Results: The mean patients’ ages were 15.6 years old. 24.2% were staging examinations and 75.8% follow-up. The mean time between acquisitions from both methods was 7.6 days. Pearson´s (-1 to 1) correlation found r=0,831 (p<0,001) for the number of positive sites and r=0,863 (p <0,001) for their major measurements, demonstrating a statistically significant and strong positive correlation. Kappa correlation found considering FDG-PET/TC as standard was 0.08004. Conclusion: WBMRI-DWI is a safe and reliable method, with very strong Pearson correlation and almost perfect Kappa, that can be used as an alternative to FDG-PET/CT on childhood, adolescent, and young adults Hodgkin lymphoma care, helping reduce later radiation toxicity.